期刊
BLOOD REVIEWS
卷 29, 期 5, 页码 329-334出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2015.03.003
关键词
Multiple myeloma; Cereblon binding molecules; IMiDs; Cereblon; Ikaros; Aiolos; Lenalidomide; Thalidomide; Pomalidomide
类别
资金
- Deutsche Forschungsgemeinschaft (DFG) [KO 4604/1-1]
Immunomodulation is an established treatment strategy in multiple myeloma with thalidomide and its derivatives lenalidomide and pomalidomide as its FDA approved representatives. Just recently the method of action of these cereblon binding molecules was deciphered and results from large phase 3 trials confirmed the backbone function of this drug family in various combination therapies. This review details the to-date knowledge concerning mechanism of IMiD action, clinical applications and plausible escape mechanisms in which cells may become resistant/refractory to cereblon binding molecule based treatment. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据